Drug profile · INN
selegiline
ELDEPRYL
selegiline (ELDEPRYL) is a monoamine oxidase b inhibitor. Associated with Orion Laboratories Pty.. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — selegiline
- US status
- approved
- Class
- —
- Route
- TRANSDERMAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
selegiline (ELDEPRYL) is a monoamine oxidase b inhibitor. Associated with Orion Laboratories Pty.. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Monoamine oxidase B inhibitor
Primary target: Amine oxidase [flavin-containing] B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is selegiline?
selegiline (ELDEPRYL) is a monoamine oxidase b inhibitor. Associated with Orion Laboratories Pty.. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for selegiline?
ELDEPRYL is a marketed brand name for selegiline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selegiline?
selegiline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.